BioCentury | Apr 12, 2021
Product Development

Sanofi sees early signs that its Synthorx acquisition could pay off with IL-2 data

Sanofi took another step in its oncology pipeline rebuild with the first clinical evidence that a cornerstone program of its oncology pipeline — precision engineered IL-2 therapy THOR-717 -- may be...
BioCentury | Apr 9, 2021
Deals

April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M

...Bio-Thera Solutions Ltd. (Shanghai:688177) for $30 million up front, plus potential milestones and royalties. The IL-6 receptor...
BioCentury | Mar 25, 2021
Emerging Company Profile

Asher Bio: aiming cytokine therapies at specific immune cells

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...
BioCentury | Mar 16, 2021
Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the machine learning-guided drug...
BioCentury | Mar 15, 2021
Product Development

As investors welcome early efficacy signal, Rubius sees platform validation in results

Rubius believes an early readout from its lead program in solid tumors represents a validating event for its RED platform, but after seeing a 13% overall response rate in a clinical study, the company is...
BioCentury | Mar 9, 2021
Product Development

AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis

Following a Phase II miss for imsidolimab to treat palmoplantar pustulosis, AnaptysBio will look ahead to five other indications for the IL-36R antagonist. The company plans to bring imsidolimab (ANB019) into Phase III testing mid-year for generalized...
BioCentury | Mar 9, 2021
Product Development

Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...did not meet its primary endpoint measuring skin fibrosis. Genentech markets the mAb against the IL-6 receptor...
BioCentury | Mar 3, 2021
Product Development

With Kymera’s clinical debut, targeted protein degradation gets its first RCT

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next quarter. The biotech announced on...
Items per page:
1 - 10 of 1492